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Abstract 
Background and Purpose: Refinement of robotic exoskeletons for overground walking is progressing rapidly. 
We describe clinicians' experiences, evaluations, and training strategies using robotic exoskeletons in spinal 
cord injury rehabilitation and wellness settings and describe clinicians' perceptions of exoskeleton benefits 
and risks and developments that would enhance utility.  
Methods: We convened focus groups at 4 spinal cord injury model system centers. A court reporter took 
verbatim notes and provided a transcript. Research staff used a thematic coding approach to summarize 
discussions.  
Results: Thirty clinicians participated in focus groups. They reported using exoskeletons primarily in 
outpatient and wellness settings; 1 center used exoskeletons during inpatient rehabilitation. A typical episode 
of outpatient exoskeleton therapy comprises 20 to 30 sessions and at least 2 staff members are involved in 
each session. Treatment focuses on standing, stepping, and gait training; therapists measure progress with 
standardized assessments. Beyond improved gait, participants attributed physiological, psychological, and 
social benefits to exoskeleton use. Potential risks included falls, skin irritation, and disappointed expectations. 
Participants identified enhancements that would be of value including greater durability and adjustability, 
lighter weight, 1-hand controls, ability to navigate stairs and uneven surfaces, and ability to balance without 
upper extremity support.  
Discussion and Conclusions: Each spinal cord injury model system center had shared and distinct practices in 
terms of how it integrates robotic exoskeletons into physical therapy services. There is currently little 
evidence to guide integration of exoskeletons into rehabilitation therapy services and a pressing need to 
generate evidence to guide practice and to inform patients' expectations as more devices enter the market. 
Video Abstract available for more insights from the authors (see Video, Supplemental Digital Content 1, available 
at:http://links.lww.com/JNPT/A231).  
INTRODUCTION 
The impairment or loss of the ability to stand and walk following spinal cord injury (SCI) results in significant 
health consequences, not only limiting mobility and performance of activities of daily living but also limiting 
functional recovery and increasing the risk for secondary complications. Secondary complications include 
pressure injuries, increased spasticity, limited joint range of motion, contractures, muscle disuse or reduced 
use atrophy, reduced bone density, increased pain (both neuropathic and musculoskeletal), depression, and 
impaired digestive, respiratory, renal, and cardiovascular function.1 Even for individuals with motor 
incomplete SCI who are able to walk, walking is generally slow, labored, uncoordinated, and variable.2 With 
intensive training, walking function sometimes can be improved, but walking speed may remain slower than 
that required for community ambulation.3 Thus, many individuals who have some motor function below their 
lesion level use a wheelchair as their primary mode of mobility. Thus, there exists a need for better 
therapeutic and mobility training devices. 
 
Potential Benefits and Limitations of Robotic Exoskeletons 
Overground robotic exoskeletons offer potential therapeutic benefits while providing intense overground 
stepping practice and, compared with some approaches, may require fewer therapists to provide assistance 
for stepping and stability during training in individuals with very limited stepping function. Other benefits of 
exoskeleton use reported in the literature include improved posture and reduced spasticity and reduced 
complications affecting cardiovascular, gastrointestinal, and renal systems.4,5 Standing may provide 
psychological benefits as well.6 Exoskeletons thus may provide an alternative strategy to realize the same 
benefits associated with other mobility training strategies.7  
Currently, however, most studies have been limited to evaluation of the safety and efficacy of robotic 
exoskeletons for individuals with SCI using the 3 main commercially available exoskeletons (Ekso, ReWalk, and 
Indego).8 Specifically, using the Indego exoskeleton,9 individuals with paraplegia transitioned to limited 
community ambulation after five, 1.5-h gait-training sessions.9 The Indego required less effort than a 
standard locked knee-ankle-foot orthoses, and participants performed strength and endurance tests 25% to 
75% faster.10 In a small, prospective study involving 8 individuals with SCI at the T1 level and below, the Ekso 
exoskeleton was used safely for overground walking when monitored by a therapist.11 In an another case 
series of 3 individuals with complete SCI, participants achieved walking speeds and distances comparable with 
persons with motor incomplete injuries, although there were no changes in volitional leg muscle activation or 
cortical activity and negligible improvement in metabolic efficiency.12 Similar safety and efficacy studies exist 
for the ReWalk exoskeleton.13-16 
 
Potential Benefits of Robotic Exoskeletons: Health Care Providers and Therapists 
Exoskeletons have the potential to decrease burden on therapists during overground walking, while 
encouraging high intensity and dosage with less fatigue compared with traditional therapy. Thus, they could 
reduce personnel costs to the health system, while potentially achieving similar functional and health 
outcomes. In contrast to treadmill, robot-based approaches, exoskeletons enable overground mobility in 
home and wellness settings for individuals who may not achieve this level of function with conventional 
therapy. However, these devices are still in their early days of development, lack strong evidence for clinical 
and cost effectiveness, and providers are exploring optimal ways of tapping the clinical and financial viabilities 
of these technologies.  
  
Given the rapid development and deployment of exoskeletons and the costs of rehabilitation, it is essential to 
learn from early adopters of robotic exoskeletons. Thus, this study obtained clinician input on the usability 
and applications of exoskeletons as part of rehabilitation services for adults with SCI (Tables 1 and 2). The aim of 
the study was to describe clinicians' experiences, evaluations, and training strategies using exoskeletons in 
rehabilitation and wellness settings. This study addresses 3 primary questions: 
 
Table 1. Robotic Exoskeletons Marketed for Rehabilitation 
Device 
Manufacturer 
FDA 
Approval 
Description Approximate 
Purchase 
Cost 
ReWalk (ReWalk 
Robotics, Inc) 
Therapy for 
personal 
mobility  
 
Independently controlled bilateral hip and knee joint motors, a 
rigid pelvic frame that links both lower limbs, ankles comprise 
double action orthotic joints with limited motion and 
adjustable spring-assisted dorsiflexion 
$75 000 
Indego (Parker 
Hannifin 
Corporation) 
 
Therapy for 
personal 
mobility 
Consists of 3 devices (small, medium, and large) including a hip 
segment and right and left thigh and shank segments.17 Four 
motors, 1 at each hip and knee joint, power movement, and 
built-in ankle-foot-orthoses support the ankles9  
Purchase price includes therapy kit, software suite, 3-d clinical 
training on-site, and storage unit 
$189 670 
 
Ekso (Ekso 
Bionics)  
 
Therapy  Incorporates hip and knee motors; adjustable, spring-assisted 
ankles with dorsiflexion/plantarflexion support assistance; 
variable/adjustable swing assistance; adjustable stance support 
and free trajectory assist; and femoral and tibial shanks 
support body weight 
 
$125 000 
Abbreviation: FDA, Food and Drug Administration 
 
 
Table 2. Manufacturers’ Guidelines for Robotic Exoskeleton Candidate Selection 
Manufacturers’ Guideline  EKSO  ReWalk  Indego 
Physician clearance 
required  
Yes  Yes  Yes 
Standing program needed  Yes  Yes  Yes 
Weight limit  <100 kg  <100 kg  <113 kg 
Height limit  152-193 cm  152-193 cm  155-191 cm 
Leg length discrepancy  Upper leg: <1.3 cm N/A  
Lower leg: <1.9 cm  
Femur range: 36-48.5 cm  
Tibia range: 43.5-56 cm 
Femur length: 35.6-47 cm 
Standing hip width  ≤45.7 cm 29-37 cm ≤42.2 cm seated 
    
ROM  Hip: ≤17◦ 
Knee: ≤12◦ 
Neutral ankle dorsiflexion 
 
Sufficient LE ROM to allow 
ambulation 
 
Sufficient shoulder, hip, 
knee, and ankle ROM, with 
functional limits for walking 
with a stability aid 
SCI level and 
completeness  
therapy ambulation T4-L5 
therapy ambulation 
T4-L5 
 C7-T3 ASIA D T4-T6 
T7-L5 community 
ambulation 
T4-T6 therapy ambulation 
T7-L5 community 
ambulation 
T4-L5 therapy ambulation 
Contraindications • ROM restrictions 
that would prevent 
a patient from 
• achieving a normal, 
reciprocal gait 
pattern, or would 
• restrict a patient 
from completing 
normal sit-to-stand 
• or stand-to-sit 
transitions 
• Spinal instability (or 
spinal orthotics 
unless cleared 
• by a medical doctor) 
• Unresolved DVT 
• Subcutaneous 
cranial bone flap 
stored in abdomen 
• Decreased standing 
tolerance due to 
orthostatic 
• hypotension 
• Significant 
osteoporosis that 
prevents safe 
standing 
• or may increase the 
risk of fracture 
caused by 
• standing or walking 
• Uncontrolled 
spasticity 
• Uncontrolled 
autonomic 
dysreflexia 
• Skin integrity issues 
on contact surfaces 
of the device 
• or that would 
prohibit sitting 
• Pregnancy 
• Uncontrolled 
spasticity or clonus 
• Fractures 
• Infection 
• Pressure injury 
• DVT 
• Severe concurrent 
medical conditions 
• Psychiatric or 
cognitive issues 
• Pregnancy 
• Lactation 
• Severe spasticity 
(Modified 
Ashworth 3) 
• Heterotopic 
ossification 
• Skin integrity issues 
• Upper extremity 
strength deficits 
• Spinal instability 
• Spinal orthotics 
• Unresolved DVT 
• Diminished 
standing tolerance 
due to orthostatic 
hypotension 
• Osteoporosis 
• ROM restrictions 
• Uncontrolled 
autonomic 
dysreflexia 
• Colostomy 
• Lower limb 
prosthesis 
• Cognitive 
impairments 
• Pregnancy or 
planning to be 
pregnant 
 
1. What are clinicians' experiences, clinical evaluations, and training strategies using robotic exoskeletons in 
rehabilitation and wellness settings? 
2. What benefits and risks of exoskeletons do clinicians perceive? 
3. What limitations of exoskeletons do clinicians identify, and what changes do they suggest for hardware and 
software development? 
 
METHODS 
Sample 
This study used qualitative methods to address the questions by organizing focus groups at 4 SCI model 
systems (SCIMS): (1) Shirley Ryan AbilityLab (formerly the Rehabilitation Institute of Chicago), (2) Craig 
Hospital, (3) Shepherd Center, and (4) TIRR Memorial Hermann. These centers chose to participate in the 
AbilityLab's collaborative module during the current SCIMS funding cycle. The focus groups occurred between 
February and April 2017, comprising primarily physical therapists with experience using robotic exoskeletons. 
Clinicians provided informed consent and received a modest honorarium. 
Procedures 
Collaborators developed a discussion guide, which the moderator used for all focus groups (see the Appendix). 
The moderator led the AbilityLab focus group in person and used videoconferencing technology to lead focus 
groups at the other 3 centers. A court reporter took verbatim notes and provided a transcript of the 
discussion. Research staff members took notes to supplement transcript reviews, which provided the basis for 
qualitative coding and analysis. 
Data Analysis 
We adopted a thematic coding approach 18 to summarize clinicians' responses to questions regarding 
patients' motivations for exoskeleton use and their perceived risks and benefits of exoskeleton use; most 
questions did not require qualitative coding as they focused on details regarding settings in which 
exoskeletons are used, eligibility criteria, assessment protocols, and other therapy procedures. For questions 
requiring qualitative coding, the procedures involved developing a codebook, testing the reliability of codes, 
summarizing data and identifying initial themes, applying code templates, connecting codes and themes, and 
corroborating and legitimating coded themes. Center principal investigators and coordinators participated in 
codebook development and transcript coding. They resolved coding discrepancies by discussing their different 
perspectives and reaching code consensus. Northwestern University's and Shepherd Center's institutional 
review boards approved the protocol. 
 
 
 
Table 3. Focus Group Participant Demographic Characteristics 
 
 
  
RESULTS 
Sample Characteristics 
Table 3 summarizes the characteristics of the 30 focus group participants. The sample represents nearly all 
therapists trained in exoskeleton use, although a few did not participate because of illness or schedule 
conflicts. They were predominantly female and white and had an average of 10 years of clinical experience. 
Most were physical therapists but included other clinical and support staff members with training and 
experience in the use of robotic exoskeletons.  
Focus Group Data 
We organize focus group data under 3 topics: (1) exoskeleton experience, clinical evaluations, and training 
strategies, (2) exoskeleton benefits and risks, and (3) exoskeleton preferences. Two investigators read the 
transcript from each of the 4 focus groups, highlighted text relevant to patients' motivation for seeking 
therapy incorporating exoskeletons and clinicians' perceptions of risks and benefits. Thematic code 
development was straightforward, given the finite range of responses and consistency of responses across 
centers. Coders achieved consensus by discussing the instances for which they initially assigned discrepant 
codes. Investigators did not code responses to questions focused on procedural details of therapy involving 
exoskeletons, given the fact-focused nature of the questions. 
 
Topic 1: Exoskeleton Experience, Clinical Evaluations, and Training Strategies 
Topic 1 included several subtopics, perceived benefits and risks of exoskeletons pertaining to therapists' 
experiences, clinical evaluations, and training strategies. Table 4 summarizes the therapists' answers to the 
discussion questions at each center. The "topic column" represents the questions posed to each of the 
groups. The table's cells contain bulleted lists summarizing the discussion. 
 
 
 
Demographic Characteristic Craig Hospital 
(n = 5) 
Shepherd Center 
(n = 10) 
Shirley Ryan 
AbilityLab 
(n = 4) 
TIRR Memorial 
Hermann 
(n = 11) 
Total (n = 30) 
Age (median years, range) 42 (33-48) 40 (28-53) 34 (30-40) 33 (29-46) 37 (28-53) 
Clinical experience (median years, range) 9 (3-20) 13 (4-30) 5 (3-6) 9 (2-22) 9 (2-30) 
Other experience (median years, range) 0 14 (3-25) 0 0 14 (3-25) 
Sex 
Female 
 
100% 
 
80% 
 
75% 
 
91% 
 
86% 
Race      
White 60% 90% 100% 82% 83% 
Asian/Indian 0% 0% 0% 9% 2% 
Multiracial 40% 0% 0% 0% 10% 
Missing 0% 10% 0% 9% 5% 
Hispanic 
Yes 
 
20% 
 
0% 
 
0% 
 
0% 
 
5% 
No 80% 90% 100% 91% 90% 
Missing 0% 10% 0% 9% 5% 
Role      
Physical therapist 100% 60% 100% 100% 90% 
Administrative 0% 10% 0% 0% 2% 
Other clinical role (exercise therapist, 0% 30% 0% 0% 8% 
 
 
 
 
  
Table 4. Summary of Robotic Exoskeleton Experience at 4 SCI Model System Centers 
Topic  
 
Craig Hospital  
 
Shepherd Center 
 
Shirley Ryan AbilityLab 
(RIC)  
TIRR Memorial 
Hermann 
In what 
settings do 
you provide 
robotic 
exoskeleton 
therapy? 
 
• Wellness 
program 
(private pay) 
• Research 
 
• Outpatient 
• Research 
(ReWalk, 
• Indego) 
• Wellness 
Program 
(private pay) 
• Outpatient 
• Research 
 
• Inpatient 
• Outpatient 
• Home use 
(private pay) 
• Research 
How do you 
use robotic 
exoskeleton
s 
in your 
practice? 
• Basic skills 
training 
(includes 
transfers, 
manual joint 
adjustment, 
don/doff, 
standing 
balance, sit 
to/from stand, 
com icator 
use, 10 MWT 
0.15 m/s, 
turning R/L18 
l collapse, byp 
edge, wall 
rest) 
• Advanced 
skills training 
(includes 
walkie-talkie, 
walking in 
busy 
environment, 
reading, door 
navigation, 
timed 
automatic 
door 
navigation, 
bench sit 
to/from stand, 
timed walking 
at crosswalk, 
ramps, side 
angle walking, 
multiple 
surface such 
as tile, carpet, 
asphalt, 10 
MWT ≥0.4 
m/s, 6MWT ≥ 
utouts 
• Weight 
bearing 
• Balance 
• Gait training 
• Cardiovascula
r health 
 
• Mobility 
• Retraining  
• Gait traini 
 
• As a 
modality to 
promote 
• neurorecove
ry 
• Gait training 
What 
criteria do 
you use to 
select 
patients 
with SCI for 
robotic 
exoskeleton
s? 
• Manufacturer’
s criteria 
• Functional 
level; use 
Indego for 
patients with 
more 
• function, Ekso 
for patients 
with less 
function 
• Resources to 
purchase 
device 
• Manufacturer’
s criteria 
• Lower 
extremity 
function 
• Recovery 
• Personal use 
• Manufacturer’s 
criteria 
• Motivation 
• Confidence 
• Cognitive ability 
• Seeking mobility 
options 
• Manufacturer
’s criteria 
• Ability to 
follow 
commands 
• Tolerate 
being upright 
• Secondary 
health 
benefits 
• No 
contraindicati
ons 
• Patient goals 
What goals 
do patients 
pursue with 
a robotic 
exoskeleton
? 
• Personal use 
training 
• Health and 
wellness 
• Personal use 
training 
• Health and 
wellness 
• Gait training 
• Personal use 
training 
•  Standing upright 
•  Gait training 
• Personal use 
training 
• Standing and 
stepping 
• Gait training 
• Self-control 
• Spasticity 
• Neurorecove
ry 
What 
motivates 
patients to 
try a 
robotic 
exoskeleto
n? 
• Exercise 
• Walking 
• Standing 
upright 
• Improved 
bowel and 
bladder 
function 
• Reduced 
spasticity 
• Exercise 
• Walking 
• Opportunity 
to try 
something 
new 
• Standing 
Balance 
• Strengthenin
g core and 
peripheral 
muscles 
• Family 
encouragement 
• Opportunity to 
try something 
new 
• Increase 
strength 
• Walking 
• Upright 
standing 
(eye-to-eye 
contact) 
• Increase 
strength 
What 
devices are 
you using? 
Indego 
Ekso 
ReWalk 
• Indego 
• ReWalk 
• Indego 
• Ekso 
• ReWalk 
• Indego and 
Ekso for 
research 
• Ekso for 
inpatient 
• ReWalk for 
outpatient 
How many 
sessions 
comprise a 
typical 
episode of 
robotic 
exoskeleto
n therapy? 
• Outpatient 
typically 6-8 
• Personal use 
up to 16 
• Variable: 
Depends on 
insurance 
and personal 
resources 
 • Inpatient: 6 
sessions, 1-h 
duration 
• Outpatient: 
15-20 for 
ReWalk 
• Outpatient: 
30 for 
independent 
How many 
staff 
members 
are 
involved in 
a therapy 
session 
using a 
robotic 
exoskeleto
n? 
• 1 PT and 1 
aide/caregiv
er 
• Varies 
depending 
on functional 
ability of 
client 
• 1 PT and 
exercise 
specialist for 
initial setup 
in wellness 
program 
• 1 exercise 
specialist 
and 1 
aide/caregiv
er for 
training in 
wellness 
program 
• 1 PT and 1 
aide for 
evaluation 
and training 
in outpatient 
program 
• 1 PT and 1 
aide/caregiver 
• 1 PT and 1 
aide 
What 
benefits do 
patients 
experience 
in using a 
robotic 
exoskeleto
n? 
• Standing 
upright 
• Weight 
bearing 
• Cardiovascul
ar 
• Reduced 
pain 
• Bowel/bladd
er benefits 
• Reduced 
spasticity 
• Sense of 
well-being 
• Increased 
trunk 
strength 
• Improved 
function 
• Reduced 
pain 
• Reduced 
spasticity 
• Reduced 
medication 
use 
• Increased 
strength 
• Improved 
ASIA scores 
• Improved 
confidence 
• Psychosocial 
benefits 
• More steps 
• Reduced 
UTIs 
• Standing upright 
• Weight bearing 
• Improved 
confidence 
• Psychosocial 
benefits 
• Improved 
function 
• More steps 
• Standing 
upright _ 
Bowel/bladd
er function 
• Gait 
• Trunk 
strength 
• Reduced 
pain 
• Reduced 
spasticity 
• Increased 
strength 
• Increased 
endurance 
• Reduced 
need for 
assistance 
• Psychosocial 
benefits 
What risks 
might 
patients 
experience 
in using a 
robotic 
• Disappointm
ent of 
expectations 
(eg, not able 
to transport 
device, still 
• Falls 
• Fractures 
• Skin 
breakdown 
• Disappointm
ent of 
expectations 
• Falls 
• Skin breakdown 
• Fracture 
risks 
• Skin 
breakdown 
exoskeleto
n? 
need 
caregiver) 
Do you use 
any 
standardize
d 
assessment
s to 
monitor 
progress in 
robotic 
exoskeleto
n therapy? 
• 10-m walk 
• 6-minute 
walk test 
• Trunk 
assessment 
• Berg Balance 
Scale 
• Document 
time up and 
walking 
• Timed Up 
and Go 
• Don and doff 
time 
• Step count 
• Rate of 
Perceived 
Exertion 
• FIM walking 
rating 
• Skills 
inventory for 
ReWalk 
• 10-m walk 
test 
• 6-minute 
walk test 
• Trunk 
assessment 
• Berg Balance 
Scale 
• Cardiovascul
ar testing 
• Range of 
motion 
• Skin 
assessment 
• Spinal cord 
assessment 
tool for 
spastic 
reflexes 
• Goals 
• ASIA 
Impairment 
Scale 
• Manual 
muscle 
testing 
• 10-m walk test 
• 6-minute walk 
test 
• Berg Balance 
Scale 
• Function in 
Sitting Test 
• Functional gait 
assessment 
• Five Times Sit to 
Stand Test 
• Metabolic 
assessment 
• Informal patient 
report 
• 10-m walk 
• 6-minute 
walk test 
• Trunk 
assessment 
Have 
patients 
purchased 
a robotic 
exoskeleto
n? 
• ReWalk (1) • Indego (2) • In process • ReWalk 
Personal 6 
(1) 
What 
robotic 
exoskeleto
n features 
would you 
like to see 
added? 
• FES 
integrated in 
exoskeleton 
• Reduce fall 
risk 
• Lighter 
weight 
• Greater 
durability 
• One hand 
free 
• Adjustable 
ankles 
• FES 
integrated in 
exoskeleton 
• Self-
balancing 
capacity 
• Dynamic 
ankle joint 
• Powered 
ankle joint 
• Capacity to 
ascend and 
descend 
stairs 
• Better fit 
• Adjustable for 
more body 
types 
• Lighter weight 
• Accommodation 
of 
thoracolumbosa
cral orthosis or 
colostomy 
• FES 
integrated in 
• exoskeleton 
• Better fit 
• Lighter 
weight 
• More 
intuitive 
user 
interface 
(battery 
level, ease, 
and clarity of 
changing 
modes), 
greater 
• Therapy flex 
mode for 
Indego 
• Capacity to 
ascend and 
descend 
stairs 
• Capacity to 
navigate 
uneven 
surfaces 
modular 
design, 
ability to 
modify 
parameters 
to adapt to 
the 
environment 
• Capacity to 
ascend and 
descend 
stairs 
• Capacity to 
navigate 
uneven 
surfaces 
• Ability to 
step 
backwards 
• Silent 
motors 
• Voice 
recognition 
feature 
• Dynamic 
standing 
option 
• Improved 
rehabilitatio
n unit 
support of 
distal lower 
extremity 
(similar to a 
personal 
unit) 
• Decreased 
friction of 
lower 
extremity 
• Cuffs over 
fibular head 
Abbreviations: ASIA D, American Spinal Injury Association D; FES, Functional Electrical Stimulation; FIM, 
Functional Independence Measure; MWT, Meter Walk Test; PT, physical therapist; RIC, Rehabilitation Institute 
of Chicago; SCI, spinal cord injury; UTIs, Urinary Tract Infection.  
Participants reported using exoskeletons for various clinical and research applications. All used exoskeletons 
in outpatient settings and community wellness facilities, with 1 center (TIRR) reporting selective use during 
inpatient rehabilitation. All SCIMS centers followed device manufacturers' patient selection criteria faithfully. 
Clinicians commented on the lack of guidance available regarding the integration of exoskeletons into 
rehabilitation therapy services. One clinician stated:  
When we were going through the training with devices we pulled some folks from inpatient, some of 
our other programs ... in order for us to get experience, but we are still trying to kind of figure out 
how, from an outpatient perspective, we are going to be utilizing the devices ... on a more regular 
basis in our centers. So really the main experience that ... [we had] are just folks who have ... decided 
to purchase a device, and ... are using their insurance benefits to come ... for training.  
Another therapist elaborated on the limited evidence base: 
 
This is a new device for us, and so we are being very systematic about what are we doing with the 
decision[s] we are making, so that people feel like they have support for the decisions that they may 
be making as an individual.... We have started in the key area of outpatient because that was a little 
cleaner, and we also ... had people that were ready to go and willing to get their personal devices.  
Clinicians emphasized the importance of screening candidates thoroughly to avoid adverse consequences: 
 
I think out in the community people are going to fall, and they probably will injure themselves, and 
whether you have 6 pounds on top of you if you are walking in of them versus 26 pounds, I think 
there is risks for injury, for fracture, for ... bone fractures or skin injury. But I think the key to that in 
reducing that is proper screening and the training that goes behind it the screening process and the 
education is really important to reduce those risks. 
 
Another focus group participant emphasized discussing patients' expectations during screening, considering 
not only physiological and functional characteristics but also psychosocial characteristics. A clinician 
commented: 
 
...screening for personal use aspect, I think what it really boils down to is us just being able to have open and 
honest conversation. It's not necessarily trying to discourage anybody from buying a device that they want, 
but ... asking them.... 'Realistically, what are your expectations? What do you expect to be able to do in this? 
And then, letting them know whether or not ... A) the device is safe to use with or do in. But ... B) taking into 
consideration ... is there a support person. Their 65-year old mom who might be in good shape but ... cannot 
necessarily offer maximum assistance if this person needs a significant amount of assistance ... we have to 
have this conversation from the very beginning. 
 
Participants reported that treatment goals typically focused on standing, stepping, and gait training. One 
center selectively provides inpatients with 6 sessions of exoskeleton training. One therapist described his or 
her approach: 
 
Our current model that we are using in inpatient is they get six sessions ... patients love getting up 
with the device, and then they kind of don't want to do anything else ... In an inpatient's world you 
have a lot of other things that have to be addressed as well, so we have kind of a limited access to it. 
 
A typical episode of outpatient exoskeleton therapy consists of 20 to 30 sessions. The minimum number of 
staff involved in an exoskeleton therapy session across centers was 2, although on occasion more staff were 
involved, depending on patients' needs.  
Standardized assessments used across centers included the 10-m and 6-minute walk tests; individual centers 
reported using a variety of balance, exertion, and manual motor tests to assess outcomes associated with 
exoskeleton training.  
Clinicians discussed the issues they consider when recommending various locomotor training strategies: 
 
If I'm only able to do 10 minutes of gait training in a robot, and I can get 35 minutes in on a treadmill, I 
think there is a dose difference there. 
 
Clinicians discussed strategies to integrate exoskeletons into rehabilitation therapy services and the 
motivational influence of exoskeletons. One clinician stated:  
... that speaks volumes to motivating them to do a lot of their other functional tasks, because some of the 
other goals they might not want to work on, but we can kind of use it as like a "carrot" and be like: "All right, if 
you do this transfer, and work on this transfer this day, then by the end of the week we will be able to try to 
get you up on the robot".... I think that has a big ... influence on a lot of other stuff we try to do. 
 
Topic 2: Exoskeleton Benefits and Risks 
Focus group participants identified a variety of perceived physiological, psychological, and social benefits and 
risks associated with exoskeleton use (Table 4). In addition to improved gait while in the exoskeleton, they 
related patient claims of improved cardiorespiratory function, reduced pain, improved bowel and bladder 
function, and improved self-confidence and self-image. Therapists also identified several risks including fall-
related injuries, skin irritation, and high patient expectations. One participant commented regarding patients' 
perceived benefits:  
[Reduced] pain and spasticity seem to be the top two. We have had some folks talk about their bowel and 
bladder, so it changes in how quickly they feel they can manage their bowel program. I had one person talk 
about sensation changes in their bladder. But again, they were also getting a lot of other interventions at the 
same time.  
Another clinician added: 
 
We've noticed changes in sensation in bowel and bladder for sure. So ability to either sense ... a full bladder, a 
need to cath or to sense the bowel program.  
Clinicians also perceived health and wellness benefits.  
Dynamic weight bearing is beneficial for ... full health ... getting just up and out of their chairs in an upright 
position. It's just for the cardiorespiratory function and also placing everything on the heart because a lot of 
people will also end up getting that ... from ... dynamic weight bearing. And then ... one thing that definitely 
should not be discounted is the psychosocial benefits, just being upright and feeling what it's like to walk 
again.  
Clinicians observed reductions in medication for spasticity and infections, saying: 
 
We have seen people significantly reduce the amount of medications that they were taking, either it was for 
spasm or for example, UTI. We had a couple of people when we did our big 40-person trial that had frequent 
UTIs, and when they were up training with the exoskeleton, their UTI significantly went away. We followed up 
a month later, and their UTI is back again.  
Participants identified psychosocial benefits across all focus groups as a salient aspect of working with robotic 
exoskeletons. For example, one clinician observed the motivating influence of exoskeleton use:  
The ability that some feel that they can stand up ... and actually being told that they will never ever walk 
again, and hearing that news, and here they are up walking, and they are like: "Can you videotape this? Can 
you video it?" So, I think ... psychosocial[ly] ... this gives them that hope that ... "Someday I may be able to 
walk again."  
Another focus group participant observed: 
 
If they feel like this [is] something that will make them get better, and stronger, and walk more and, ..., in a 
better pattern, then they will give it a try and they will be willing to see what it has to offer for them.  
Several therapists identified the psychosocial benefit of being upright and facing others eye-to-eye as a 
reported benefit:  
Feeling more engaged in social situations rather than ... being in a chair looking up and you can't really hear 
what people are saying in a crowded room. That some of those psychological changes of ... being able to look 
at people eye-to-eye. I know we hear that a lot, but it really is extremely important to our folks that are used 
to being at chair level. 
A common comment people say, "It's just nice to look someone in the eyes, and not be looking up at the 
world."  
Participants also described the critical role of patients' expectations, the risks of disappointment, and how 
expectations change over time.  
... The other thing that I think is really critical are patient expectations. I think in this room we are all 100 
percent, it's about the patient, but we also have to be open and honest with them about how they can really 
use these systems, and unless they come and try it, they won't know. We had a guy that wanted to purchase 
one of the systems, and his goal was to get up and ... use it all day at work ... drive with it in his car and all of 
that, and this was somebody that was part of our research program previously. And I don't know if he forgot 
or what, but it was about almost a year between the end of research and when this individual chose to buy 
one of the systems, and then when he came to try the system it was like: "Oh, well, I don't think I would use 
this every day." ... They have this fantasy it's going to get rid of their wheelchair or whatever, and that's just 
not the case, and that's another important aspect of giving patients a choice.  
Participants noted the challenges patients encountered in seeking services to use an exoskeleton: 
 
From a funding standpoint, it's very challenging for anybody to get funding to purchase one, and then to ... 
find places where therapists are trained on how to use them, but then also be able to access them even if 
they don't have that funding.  
Another therapist noted the potential burden on volunteer caregivers using an exoskeleton: 
One thing to also keep in mind is how taxing is it for the caregiver or the therapist to provide the assistance and 
the training.  
This comment contrasts with sources that anticipate reduced physical burden on caregivers and therapists 
during training.19 
 
Topic 3: Exoskeleton Preferences 
Focus group participants identified several enhancements they would like to see in exoskeletons (Table 4). 
Some patients also anticipate technology improvement, as one therapist noted:  
He was still hesitant to purchase the [device] at this time. He was more interested in seeing what future technology 
[may bring] ... maybe something a little bit less cumbersome, looking for something more streamlined. So he wants 
his other equipment. I think he is just waiting for future technology. 
DISCUSSION 
Clinicians at each SCIMS center revealed similar practice patterns in terms of how they integrate robotic 
exoskeletons into physical therapy services. All SCIMS centers adhere to manufacturers' and Food and Drug 
Administration's (FDA's) guidance on device use but deploy exoskeletons in different settings and adopt different 
clinical evaluations. This variability likely reflects both institutional culture and the minimal evidence from 
randomized controlled trials and clinical studies to guide implementation and standardize practice 
guidelines.5 Clinicians who deliver robotic exoskeleton therapy mostly include physical therapists with specialist 
certification achieved through manufacturers' training. Many centers employ exercise specialists in addition to 
physical and occupational therapists. ReWalk certifies individuals without a clinical background. While clinician 
training and costs were not a focus of the focus group discussion guide, the costs associated with the delivery of 
robotic exoskeleton therapy reflect clinicians' education and training, and therefore costs vary according to the 
qualifications of the personnel who provide the training. Clinicians recognized the marketing value of offering 
exoskeletons, noting that some patients sought out the collaborating facilities for physical therapy services because 
they offered use of robotic exoskeletons. Therapists recognize that some patients who express interest in 
exoskeletons may not meet the criteria for use of these devices. As with any intervention, therapists offer education 
and guidance about approaches that are most appropriate to the patients' functional status, goals, and prognosis for 
achieving those goals.  
Clinicians identified a variety of secondary benefits from exoskeleton use. They observed psychological and 
social benefits including satisfaction from making eye contact while standing to improved bladder and bowel 
sensation and function, which allows greater ease in social activities. According to the clinicians, patients do 
not voice secondary benefits as reasons for pursuing exoskeleton therapy, but many were pleased with these 
benefits.  
Clinicians observed that robotic exoskeleton technology continues to evolve rapidly, limiting their adoption of 
devices to avoid early obsolescence. Although currently there are only 4 devices that are FDA approved, the 
software and hardware of these devices have changed numerous times in the last decade, making standard 
evaluations, fitting, and training difficult. To complicate issues further, the FDA will likely approve a dozen 
new devices in the coming years. Thus, larger institutions are creating exoskeleton teams with therapists with 
training, certification, and up-to-date information on the evolving rehabilitation robotics market.  
Participants reported that patients voiced awareness of the pace of technological development as a 
consideration in device purchases. For example, Shepherd Center's use of exoskeletons is evolving quickly as 
its staff considers optimal and cost-effective ways to integrate them in therapy services. Ultimately, patient 
demand for robotic exoskeletons motivates facilities to investigate purchase and use of this modality. For 
example, TIRR Memorial Hermann provides access to exoskeleton use for inpatients so that they may try a 
novel technology for overground walking that they might not have access to after discharge. Patients' ability 
to purchase a personal mobility exoskeleton reflects a variety of considerations including individuals'  
resources. Locomotor training with exoskeletons also increased rapidly during the course of this study, with 
the AbilityLab reporting considerable growth of device use after moving to a new facility with expanded 
inpatient, outpatient, and home training clinics.  
Several study design features limit the generalizability of the findings. Results reflect the experience of only 4 
centers, all of which are part of the SCIMS; they may not be representative of all hospitals providing SCI 
rehabilitation nationally. Clinicians had the opportunity to decline study participation, though nearly all 
clinicians involved in robotic exoskeleton service delivery participated. Despite efforts to create a 
nonevaluative climate, the group format may have limited their willingness to voice opinions that conflicted 
with leadership and peer perspectives.  
This study focused on therapists' perspectives due to their unique understanding and skill with exoskeleton 
use and physical functioning. Future studies should seek patients' perspectives in device selection and 
evaluation. We need a fuller understanding of the individual-, facility-, and societal-level costs and benefits 
associated with robotic exoskeleton use in clinical and wellness applications. 
 
CONCLUSIONS 
This study provides insight into the issues facilities face and the considerations clinicians use in delivering 
robotic exoskeleton therapy and extends our knowledge of users' perspectives.20 The 4 SCIMS centers 
involved in the study have similar practice patterns in terms of how they integrate overground robotic 
exoskeletons into physical therapy services. While they adhere to manufacturers' and FDA's guidance on 
device use, only 1 study center deploys exoskeletons during inpatient rehabilitation currently. Clinicians at all 
study centers described patients' report of bowel, bladder, and psychosocial benefits in addition to improved 
gait. The study centers educate patients on rapid technology development when they recommend devices to 
patients contemplating purchases for personal mobility. An unintended effect of these devices may be to 
engage patients more fully in their rehabilitation quite apart from walking or promoting neuromotor recovery 
by offering hope when patients struggle to see a positive future. There is currently little evidence to guide and 
standardize the integration of exoskeletons into rehabilitation therapy services and a pressing need to 
generate evidence to guide practice and to inform patients' expectations. A valuable next step would be to 
convene a technical expert panel to draft consensus guidelines on device use. Clinics considering use of 
robotic exoskeletons should define the therapy goals that are amenable to the hardware and software 
capabilities of specific exoskeletons; select patients who are likely to benefit from exoskeleton therapy based 
on institutional pilot testing, early studies, and manufacturers' guidelines; and develop strategies to ensure 
that patient expectations are realistic to obtain maximum benefit for therapy and personal mobility. Based on 
SCIMS Centers' experience, we recommend that facilities sites.  
1. complete training recommended by device manufacturers; 
2. become familiar with indications and contraindications for specific devices; 
3. adjust goals and protocols to individual patient's circumstances and needs; 
4. notify manufacturers of device malfunctions or repair needs; 
5. maximize patients' contributions by weaning them slowly off the motors progressively; 
6. monitor skin at all areas that contact the device before and after use; 
7. encourage users to provide feedback while using the device and adjust device settings accordingly; 
8. progress through a device's modes to facilitate learning and achieve specific goals; 
9. apply gait training strategies with application of frequency, intensity, time, and type (FITT) principle to use 
the device effectively and optimize patients' outcomes; and 
10. monitor patients' cardiovascular, integumentary, and neuromuscular responses to exoskeleton sessions.  
We recommend that facilities not 
 
1. use devices with patients who have open skin lesions or wounds in the areas that contact the exoskeleton; 
2. use an exoskeleton device with a patient who is uncomfortable with the technology; 
3. assume that the device will prevent falls-continue to use usual guarding techniques; 
4. force the fit of the device. If a patient's fit is borderline, err on the side of caution; and 
5. use the same software program in an exoskeleton for all patients. 
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APPENDIX Focus Group Discussion Guide for Therapists With Robotic Exoskeleton 
Experience 
1. How do you use robotic exoskeletons in your practice? 
a. What criteria do you use to select patients with SCI for exoskeletons use? 
b. What latitude do you have in selecting patients for exoskeletons use? 
c. What makes/models do you use? 
d. Why do you use these models? 
e. What kinds of modifications would you like to have made to robotic exoskeletons? Why? 
f. How many clinicians are present when a patient is learning to use a robotic exoskeleton? If any, are they therapists? Aides? 
What are their qualifications? 
g. What does a typical exoskeleton therapy session look like? What's the breakdown of time spent on what activities. (If the 
answer is "it depends"-ask) It depends on what? Please give an example. 
h. Would you use the same number of therapists and aides for conventional therapy for the patient who uses an exoskeleton 
based on the answer to the previous question? 
2. What standardized assessments do you use to assess patients' progress using an exoskeleton? 
3. Do you work with patients who use exoskeletons in the community? 
a. What motivates patients to use exoskeletons in the community? 
b. What facilitates their use of exoskeletons in the community? 
c. What limits their use of exoskeletons in the community? 
d. What risks have patients experienced using exoskeletons in the community? 
e. What risks are you concerned about? 
4. What benefits do patients receive from exoskeletons use in the clinic? 
a. What kinds of physical benefits? 
b. What about social benefits? 
c. What about occupational benefits? 
d. Any emotional benefits? 
e. Any other benefits? 
5. What risks or harm have patients experienced using an exoskeleton? 
a. What kinds of physical harms? 
b. What about social harms? 
c. What about occupational harms? 
d. Any emotional harms? 
e. Any other harms? 
6. What aspects of the device, patient, or environment facilitate benefit? 
a. Patient characteristics? 
b. Device characteristics? 
c. Environmental characteristics? 
7. What aspects of the device, patient, or environment limit device benefit? 
a. Patient characteristics? 
b. Device characteristics? 
c. Environmental characteristics? 
8. Have any of your patients purchased exoskeletons? 
a. What kinds of patients? 
b. What kinds of devices? 
c. What kinds of activities? 
9. What other aspects of exoskeleton use or therapy that we have not discussed would you like to mention or add? 
 
